阿斯利康AstraZeneca plc (AZN) 2023年年度报告「LSE」.pdf

1、What science can doAstraZeneca Annual Report and Form 20-F Information 2023 What science can doWe are a global,science-led,patient-focused pharmaceutical business,committed to excellence in the research,development and commercialisation of prescription medicines.We aim to transform the lives of pati

2、ents with improved outcomes and a better quality of life.We are using data,digital technologies and artificial intelligence to transform our business,accelerate our science and maximise our impact for people,society and the planet.See what we are doing in this area on page 6.Our SupplementsDetailed

3、information on our Development Pipeline,Patent Expiries of Key Marketed Products,Risk and Task Force on Climate-related Financial Disclosures(TCFD)Statement.See our website, For more information within this Annual Report.For more information,see .BV Denotes sustainability information independently a

4、ssured by Bureau Veritas.CVRM diseases are complex and interconnected.Its by understanding their interconnections and targeting the mechanisms that drive them that well be able to detect,diagnose and treat people earlier and more effectively,stop disease progression and,ultimately,improve and save t

5、he lives of the millions of patients living with these diseases.Front cover image:Cardiovascular,Renal and Metabolic(CVRM)diseases.Use of terms:In this Annual Report,unless the context otherwise requires,AstraZeneca,the Group,we,us and our refer to AstraZeneca PLC and its consolidated entities.Welco

6、me zDenotes a scale break.Throughout this Annual Report,all bar chart scales start from zero.We use a scale break where charts of a different magnitude,but the same unit of measurement,are presented alongside each other.For more information in relation to the inclusion of Reported performance,Core f